Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 731-735

  Angelini, Antonio ^a   Iezzi, Manuela ^a   Di Febbo, Concetta ^a   Di Ilio, Carmine ^a   Cuccurullo, Franco ^a   Porreca, Ettore ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Curcumin; Ibuprofen; Multidrug resistance; Non steroidal anti inflammatory drugs; NS 398; P glycoprotein; Sulindac; Verapamil

Indexed keywords

CURCUMIN; DOXORUBICIN; GLYCOPROTEIN P; IBUPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; VERAPAMIL;

APOPTOSIS; ARTICLE; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG RETENTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MONOTHERAPY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; TREATMENT OUTCOME; UTERUS SARCOMA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; P-GLYCOPROTEIN; SARCOMA;

EID: 54949102358     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000067     Document Type: Article

References (30)

1. Ling V: Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 40: 3-8, 1997.
2. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976.
3. Pastan I and Gottesman MM: Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393, 1987.
4. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398, 1991.
5. Nooter K and Stoter G: Molecular mechanism of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768-780, 1996.
6. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
7. Seeber S, Asieka R, Schmidt CG, Achterrath W and Crooke GT: In vivo resistance towards anthracycline, etoposide and cisdiaminedichloroplatinum. Cancer Res 42: 4719-4725, 1982.
8. Endicott JA and Ling VZ: The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
9. Higgins CF: ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992.
10. Raviv Y, Pollard HB, Bruggermann EP, Pastan I and Gottesman MM: Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265: 3975-3980, 1990.
11. Sauna ZE, Smith MM, Muller M, Kerr KM and Ambudkar SV: The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33: 481-491, 2001.
12. Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283, 2000.
13. Borowski E, Bontemps-Gracz MM and Piwkowska A: Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 52: 609-627, 2005.
14. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10: 159-165, 2003.
15. Sarkadi B and Müller M: Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 8: 171-182, 1997.
16. Twentymann PR and Bleehen NM: Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporine. Eur J Cancer 7: 1639-1642, 1991.
17. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Shellens JH and van Tellingen O: Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6: 4416-4421, 2000.
18. Green LJ, Marder P and Slapak CA: Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61: 1393-1399, 2001.
19. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L and Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40: 13-19, 1997.
20. Andrews P, Zhao X, Allen J, Fengmin L and Chang M: A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cance cells in vitro. Cancer Chemother Pharmacol 61: 203-214, 2008.
21. Zha S, Yegnasubramanian V, Nelson WG, Isaac WB and De Marzo AM: Cyclooxygenase in cancer: progress and perrpective. Cancer Lett 215: 1-20, 2004.
22. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O and Spano JP: Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59: 51-64, 2006.
23. Smith ML, Hawcroft G and Hull MA: The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36: 664-674, 2000.
24. Howe LR and Dannenberg AJ: A role for cyclooxygenase-2-inhibitors in the prevention and treatment of cancer. Semin Oncol 29: 111-119, 2002.
25. Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V and Roselli M: Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res 27: 3147-3162, 2007.
26. Harker WG and Sikic BI: Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45: 4091-4096, 1985.
27. Wesolowska O, Paprocka M, Koziak J, Motohashi N, Dus D and Michalak K: Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res 25: 383-389, 2005.
28. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
29. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-63, 1983.
30. Shan K, Lincoff AM and Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47-58, 1996.